

4
1

Name of Journal: *World Journal of Gastroenterology*

Manuscript No: 54071

Manuscript Type: CASE REPORT

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports

Apolonia Novillo, María Gaibar, Alicia Romero-Lorca, María Fuencisla Gilsanz, Laura Beltrán, Miguel Galán, Beatriz Antón, Diego Malón, Amalia Moreno, Ana Fernández-Santander

Abstract

BACKGROUND

In metastatic colorectal cancer (mCRC), the anti-vascular endothelial growth factor drug bevacizumab (BVZ) plus chemotherapy significantly improves

Match Overview

1	Internet 38 words crawled on 26-Feb-2019 www.nature.com	1%
2	Internet 29 words crawled on 12-Apr-2020 cancerbiomedcentral.com	1%
3	Crossref 18 words Chun Chen, Zhuo-Qing Xu, Ya-Ping Zong, Bao-Chi Ou, Xiao-Hui Shen, Hao Feng, Min-Hua Zheng, Jing-Kun Zhao, Ai-G	1%
4	Internet 14 words crawled on 11-Oct-2013 www.redorbit.com	<1%
5	Internet 14 words crawled on 30-Mar-2020 clinical-experimental-nephrology.imedpub.com	<1%
6	Internet 13 words crawled on 30-Nov-2019 ascopubs.org	<1%
7	Internet 13 words crawled on 13-Jul-2019 theoncologist.alphamedpress.org	<1%
8	Internet 12 words crawled on 27-Feb-2020	<1%

Efficacy of bevacizumab-containing chemotherapy in me



ALL

IMAGES

VIDEOS

15,600 Results

Any time ▼

[Efficacy of bevacizumab and chemotherapy in the first-line ...](#)

<https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-015-0266-6> ▼

Mar 24, 2015 - Background. The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with **metastatic colorectal cancer** (mCRC) treated with bevacizumab (bev) plus **chemotherapy** in the first-line setting.

Cited by: 11

Author: Beatrix Bencsikova, Zbynek Bortlicek, Ja...

Publish Year: 2015

[Bevacizumab in the therapy for refractory metastatic ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2727788>

The addition of **bevacizumab** to **active chemotherapy** has further improved survival when used in the first and second lines of **therapy for metastatic colorectal cancer**. Evidence supporting the continued **use of bevacizumab** throughout lines of **therapy** is accumulating.

Cited by: 7

Author: Mary F Mulcahy

Publish Year: 2008

[Role of bevacizumab in colorectal cancer growth and its ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746376>

Aug 21, 2013 - Currently, the combination of the novel targeted therapy agents irinotecan, capecitabine and bevacizumab is the most widely used in **metastatic colorectal cancer** resulting in increased response rates[23,24,27,28]. Bevacizumab is the first agent to affect survival in patients with **metastatic colorectal cancer**, improving survival by 30%.

Cited by: 73

Author: Efstathios T Pavlidis, Theodoros E Pavlidis



15,600 Results

Any time ▾

[Role of bevacizumab in colorectal cancer growth and its ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3746376>

Aug 21, 2013 · Currently, the combination of the novel targeted therapy agents irinotecan, capecitabine and bevacizumab is the most widely used in **metastatic colorectal cancer** ... +

Cited by: 73

Author: Efstathios T Pavlidis, Theodoros E Pavlidis

Publish Year: 2013

[Efficacy of bevacizumab and chemotherapy in the first-line ...](#)

<https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-015-0266-6>

Mar 24, 2015 · Background. The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in ... +

Cited by: 11

Author: Beatrix Bencsikova, Zbynek Bortlicek, Ja...

Publish Year: 2015

[Angiogenesis-related protein expression in bevacizumab ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4579833>

YILDIZ et al. (2010) evaluated the **expression** of VEGFR3 by immunohistochemistry in tumor samples from **metastatic colorectal cancer** patients treated with **chemotherapy** and bevacizumab and ... +

Cited by: 15

Author: Tadeu Ferreira Paiva, Victor Hugo Fonse...

Publish Year: 2015

[KRAS mutation and primary tumor ... - Scientific Reports](#)

<https://www.nature.com/articles/s41598-017-14669-2>

Oct 30, 2017 · Sun, D., Shi, Y., Wang, Y. et al. KRAS mutation and primary tumor location do not affect **efficacy of bevacizumab-containing chemotherapy** in stage IV **colorectal cancer** patients.

Cited by: 4

Author: De-cong Sun, Yan Shi, Yan-rong Wang, Y...

Publish Year: 2017

[Hypertension and overall survival in metastatic colorectal ...](#)

<https://www.nature.com/articles/bjc20112>

Feb 08, 2011 · Hypertension (HTN) is a common **toxicity** of anti-VEGF (vascular endothelial growth factor) **antibody treatment**. It may be a marker of VEGF signalling pathway ... +